Radiotherapy and Paclitaxel Plus Pazopanib or Placebo for Anaplastic Thyroid Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial
Lancet Oncol 2023 Jan 18;[EPub Ahead of Print], EJ Sherman, J Harris, KC Bible, P Xia, RA Ghossein, CH Chung, N Riaz, GB Gunn, RL Foote, SS Yom, SJ Wong, SA Koyfman, MF Dzeda, DA Clump, SA Khan, MH Shah, K Redmond, PA Torres-Saavedra, QT Le, NY LeeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.